GLAUCOMA SURGERY

GLAUCOMA SURGERY

GOLD SHUNT – GMS PLUS+

Gold Shunt Overview

Gold_shunt

The Gold Shunt, GMS PLUS+, is a novel, minimally invasive device that has the potential to advance the surgical treatment of glaucoma. Developed in collaboration with experienced engineers and leading glaucoma surgeons, the device is the first biocompatible, pure gold implant that uses the eye’s natural pressure differential to reduce intraocular pressure (IOP). Differentiated from other surgical glaucoma options, the results are achieved without creating a bleb, a common source of serious medical complications.

The Gold Shunt is an investigational device currently being studied in a multi-center clinical trial and is not available for use in the United States. The device is currently approved for use in Canada as well as in select countries in Europe.

 

 

Key features of the Gold Shunt device include:

  • SAFETY: No bleb-related complications, highly biocompatible material
  • EFFICACY: Novel mechanism of action, advanced engineering to optimize performance
  • REPRODUCIBLE: Industrialized surgical procedure, familiar technique

Procedure

I-MED Pharma and SOLX have collaborated with leading glaucoma surgeons to develop a precise, familiar surgical technique. The end result is an industrialized and highly reproducible procedure that can be performed in an outpatient setting.

Ologen® COLLAGEN MATRIX
ologen
Ologen® Collagen Matrix (ologen® CM) is an advanced wound care device composed of a porous matrix of cross-linked atelocollagen and glycosaminoglycan. ologen® Collagen Matrix is specifically designed to promote scar-less wound healing without the use of MMC in glaucoma & other ophthalmic surgeries. ologen® Collagen Matrix enables scar-less wound healing with a prominent healthy vascular bleb as opposed to the MMC induced, thin, avascular bleb with late complications of bleb leakage, blebitis, and endophthalmitis. The dangers of handling MMC are avoided. The surgery is made more time efficient by eliminating the need for handling, application and disposal of MMC.

 

 

 

 

 

 

iOPtima 

IOPtima Ltd. has developed the IOPtimate system, a unique CO2 laser-assisted system for the treatment of Glaucoma.

The IOPtimate system is intended to treat patients with primary Open-Angle Glaucoma (POAG) and Pseudo-Exfoliative Glaucoma (PEXG). Notwithstanding, IOPtima has already accumulated a very positive experience in combined surgeries (Cataract and Glaucoma).

In utilizing the particular properties of the CO2 laser, the IOPtimate system, thins the sclera wall via ablating surges at the Schlemm’s Canal area without penetrating the scleral wall, thereby reducing IOP by facilitating adequate, functional percolation of intra-ocular fluid from the eye through the remaining membrane in a simple and highly controlled and specific manner.

As infrared CO2 laser radiation is absorbed and blocked by water and aqueous solutions, it is therefore ineffective in ablating when applied over wet tissues, thus does not allow the procedure to penetrate into the eye like other invasive procedures.

Therefore, the remaining thin scleral layer remains intact, without penetration into the eye, which is known to be the source of most ophthalmic surgery complications, adverse events and side effects.

The iOPtimate System Components: 

The Laser & Control Unit
The surgeon chooses the program parameters on the LCD touch-screen and initiate the laser operation.

The Scanner
The Scanner is connected to the control unit, attached to the microscope and operated by a foot-switch. By using a sophisticated system of servo-engines and optics, the scanner takes the laser beam and accurately ablates the sclera as per the pre-selected area and pattern.